TelyRx Holdings Inc. faces a challenging trading session, with shares dropping significantly.
TelyRx Holdings Inc. (TELY.TO) is seeing a decline in its stock price, down 1.82% today, closing at CA$2.70. This drop is significant, especially considering the company's recent financial results and market activity.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeMarket cap
$73.09M
52W high
$4.25
52W low
$2.00
1W change
-4.51%
Analyst Price Targets
Based on analyst covering TELY
Wall Street analysts forecast TELY stock price to rise 118.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+118.2% Upside
Current Price
C$2.75
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
107.5%
Annualized
90-Day Vol
102.2%
Annualized
Trend (90d)
-36.5%
Annualized drift
90d Mean
C$2.41
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.63 | C$1.82 – C$3.82 |
| 60 trading days | C$2.52 | C$1.49 – C$4.26 |
| 90 trading days | C$2.41 | C$1.27 – C$4.59 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should stay cautious as TelyRx navigates its post-IPO landscape, particularly given its growing net losses despite revenue growth.
TelyRx Reports CA$4.7 Million Net Loss
The company reported a net loss of CA$4.7 million in Q1 2026, up from CA$3.1 million in Q4 2025. This highlights the challenges TelyRx faces in managing its expenses while trying to scale operations.
Bull case
Despite the current downturn, TelyRx's revenue growth in Q1 2026 shows potential. The increase suggests that the company could become profitable if it can improve its operational efficiencies.
Bear case
However, the significant net loss in the latest quarter raises concerns about the company’s financial health. Investors worry about TelyRx's ability to sustain growth without needing more capital.
Recent Financial Performance
Advertisement
TelyRx Holdings Inc. reported a revenue increase to CA$19.4 million in Q1 2026, up from CA$14.3 million in the previous quarter. Still, the net loss of CA$4.7 million compared to a loss of CA$3.1 million in Q4 2025 is troubling. This pattern of rising losses, even with revenue growth, is a warning sign for investors.
Market Reaction and Investor Sentiment
The stock's 1.82% decline today reflects investor concerns about TelyRx's ability to turn revenue growth into actual profits. With a market cap of CA$73.1 million, the company’s financial health will be closely watched as it continues its post-IPO journey.
Looking Ahead
As TelyRx Holdings Inc. moves forward, investors will be paying close attention to any signs of operational improvements and cost management strategies that could help reduce losses. The upcoming quarters will be critical in determining whether the company can reverse its financial trajectory.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
